Yes, Belsomra (suvorexant) is a Schedule IV controlled substance under the Controlled Substances Act. The DEA finalized this classification on September 29, 2014, placing it in the same regulatory category as other prescription sleep medications like zolpidem (Ambien) and eszopiclone (Lunesta). Schedule IV means the drug has a recognized medical use but carries some potential for abuse or dependence, though lower than substances in Schedules I through III.
Why Belsomra Is Classified as Schedule IV
Any prescription sleep aid that can cause sedation or euphoria gets scrutiny from the DEA before reaching pharmacies. Belsomra earned its Schedule IV placement because it affects brain chemistry in ways that could, in theory, be misused. That said, it works through a fundamentally different mechanism than older sleep drugs, which factors into its relatively lower abuse profile.
Traditional sleep medications typically amplify the brain’s main calming chemical (GABA), producing broad sedation. Belsomra instead blocks orexin receptors, the signaling system your brain uses to promote and sustain wakefulness. Rather than forcing sedation, it dials down the wake signal, letting sleep happen more naturally. This distinction matters because clinical trials found no evidence of physical dependence with prolonged use and no withdrawal symptoms after stopping the medication.
What Schedule IV Means for You
Because Belsomra is a controlled substance, there are practical rules around how you get and refill it. Your prescriber can authorize up to five refills within a six-month window, but you’ll need a new prescription after that. Pharmacies track controlled substance dispensing, and in most states your fill history is logged in a prescription drug monitoring program (PDMP).
You cannot legally share Belsomra with someone else, even if they have the same sleep problems. Carrying it while traveling is fine as long as it’s in the original labeled bottle from your pharmacy.
Abuse and Dependence Potential
In completed clinical trials, researchers found no evidence of physical dependence even with prolonged use. When patients stopped taking Belsomra, there were no reported withdrawal symptoms. Studies also looked specifically at rebound insomnia, the common pattern where sleep gets temporarily worse after stopping a medication. No clear rebound effects were observed at any of the tested doses.
This profile is notable compared to some older sleep medications, where tapering is often recommended to avoid rebound symptoms. Belsomra’s orexin-blocking mechanism appears to carry a lower risk on this front, which is one reason researchers describe it as promoting sleep “without causing rebound insomnia or risk of dependence.”
Next-Day Impairment
One practical concern with any controlled sleep medication is how it affects you the following morning. The FDA evaluated Belsomra’s impact on driving performance nine hours after dosing. In adults under 65, both the 20 mg and 40 mg doses showed clinically meaningful driving impairment in some subjects after a single night of use. Interestingly, in adults 65 and older, neither the 15 mg nor 30 mg dose produced a statistically significant effect on driving.
The recommended starting dose is 10 mg, taken no more than once per night within 30 minutes of going to bed. You should have at least 7 hours remaining before you need to wake up. Starting at the lower dose and allowing a full night’s sleep reduces the chance of morning grogginess.
The Narcolepsy Connection
Belsomra’s mechanism creates an important contraindication worth understanding. Narcolepsy, the condition that causes sudden sleep attacks and muscle weakness, is caused by a loss of the same orexin-producing neurons that Belsomra blocks. People with narcolepsy already have a broken orexin system. Taking a drug that further suppresses orexin signaling could worsen their symptoms, potentially triggering episodes of cataplexy (sudden muscle weakness triggered by emotions). This is why Belsomra should not be used by anyone with narcolepsy.
For people without narcolepsy, the temporary, reversible blockade of orexin receptors does not carry this same risk. The drug wears off as it’s metabolized, and the orexin system resumes normal function.